Find a Tender · Contract
Ustekinumab and Omalizumab
A public procurement published by The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS) via Find a Tender.
- —
- Award value
- £70m
- Tender value
- 7
- Suppliers
- 8
- Awards
- 2
- Notices
- Contract
- Stage
Overview
Supply of Ustekinumab and Omalizumab to NHS Scotland
Key details
- Source
- Find a Tender
- Lifecycle stage
- Contract
- Status
- active
- CPV classification
- 33600000 — Pharmaceutical products
- Currency
- GBP
- Total award value
- —
- Tender value
- £70,000,000
- First published
- 28 Jun 2024
- Last updated
- 11 Sept 2024
Awards
8 awards recorded on this procurement.
| Supplier | Companies House | Awarded | Status | Value |
|---|---|---|---|---|
| Accord Healthcare Ltd | 04596349 | — | active | — |
| Amgen Ltd | 02354269 | — | active | — |
| Celltrion Healthcare United Kingdom Limited | 11685363 | — | active | — |
| Janssen-Cilag Ltd | 01027904 | — | active | — |
| Sandoz | 01547204 | — | active | — |
| STADA UK - Thornton & Ross | — | — | active | — |
| Celltrion Healthcare United Kingdom Limited | 11685363 | — | active | — |
| Novartis Pharmaceuticals UK Ltd | 00119006 | — | active | — |
Notice timeline
Every published notice in this procurement's lifecycle.
All suppliers
Frameworks & programmes
More from The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)
FAQs about this procurement
Who is the buyer for "Ustekinumab and Omalizumab"?
Ustekinumab and Omalizumab is a UK public-sector procurement published by The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS) via Find a Tender.
Has "Ustekinumab and Omalizumab" been awarded?
Yes — 8 awards are recorded, with a reported total value of £70,000,000. The current lifecycle stage is "Contract".
Which suppliers are involved in "Ustekinumab and Omalizumab"?
7 suppliers are linked: Accord Healthcare Ltd, Amgen Ltd, Celltrion Healthcare United Kingdom Limited, Janssen-Cilag Ltd, Sandoz, STADA UK - Thornton & Ross, Novartis Pharmaceuticals UK Ltd.
What is "Ustekinumab and Omalizumab" worth?
The reported tender value is £70,000,000.
When was "Ustekinumab and Omalizumab" published?
It was first published on 28 Jun 2024 and last updated on 11 Sept 2024, across 2 notices.
Track procurements like this one
Enable monitors the entire UK public-contract pipeline — get alerts on buyers, suppliers and frameworks that matter to you.
Get in touch with Enable